Literature DB >> 17704983

[Management of capecitabine-induced hand-foot syndrome by local phytotherapy].

Elisabeth Kern1, Manuela Schmidinger, Gottfried J Locker, Brigitte Kopp.   

Abstract

The so-called hand-foot syndrome (HFS) is a dose-limiting side effect with only rare therapeutic options in cancer patients treated with capecitabine (Xeloda). Depending on the intensity of the skin reaction dose reduction, interruption or even the break-off of capecitabine therapy is necessary. We therefore try to describe a new and promising alternative treatment of the hand-foot syndrome, a local therapy with a mixture of herbal medicinal products mainly consisting of hand- and foot baths, and present the promising results of this treatment modality observed in 11 consecutive patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704983     DOI: 10.1007/s10354-007-0435-5

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  11 in total

1.  Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.

Authors:  A M Lopez; L Wallace; R T Dorr; M Koff; E M Hersh; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

2.  Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acid.

Authors:  D Baricevic; S Sosa; R Della Loggia; A Tubaro; B Simonovska; A Krasna; A Zupancic
Journal:  J Ethnopharmacol       Date:  2001-05       Impact factor: 4.360

3.  Anti-oedematous activities of the main triterpendiol esters of marigold (Calendula officinalis L.).

Authors:  K Zitterl-Eglseer; S Sosa; J Jurenitsch; M Schubert-Zsilavecz; R Della Loggia; A Tubaro; M Bertoldi; C Franz
Journal:  J Ethnopharmacol       Date:  1997-07       Impact factor: 4.360

4.  Treatment of cytarabine acral erythema with corticosteroids.

Authors:  J Brown; K Burck; D Black; C Collins
Journal:  J Am Acad Dermatol       Date:  1991-06       Impact factor: 11.527

5.  Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.

Authors:  Ismail Oguz Kara; Berksoy Sahin; M Erkisi
Journal:  Breast       Date:  2005-09-26       Impact factor: 4.380

Review 6.  Management of hand-foot syndrome induced by capecitabine.

Authors:  Sarah M Gressett; Brad L Stanford; Fred Hardwicke
Journal:  J Oncol Pharm Pract       Date:  2006-09       Impact factor: 1.809

7.  Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.

Authors:  D M Vail; R Chun; D H Thamm; L D Garrett; A J Cooley; J E Obradovich
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

Review 8.  Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Authors:  Werner Scheithauer; Joanne Blum
Journal:  Oncology (Williston Park)       Date:  2004-08       Impact factor: 2.990

Review 9.  Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).

Authors:  Hilde Marsé; Eric Van Cutsem; Axel Grothey; Sonia Valverde
Journal:  Eur J Oncol Nurs       Date:  2004       Impact factor: 2.398

10.  Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.

Authors:  Edward Lin; Jeffrey S Morris; Gregory D Ayers
Journal:  Oncology (Williston Park)       Date:  2002-12       Impact factor: 2.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.